Language:

Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes

The New England journal of medicine, 2015-10, Vol.373 (18), p.1709-1719 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1510188 ;PMID: 26466202

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes
Author: Kaul, Upendra ; Bangalore, Sripal ; Seth, Ashok ; Arambam, Priyadarshini ; Abhaychand, Rajpal K ; Patel, Tejas M ; Banker, Darshan ; Abhyankar, Atul ; Mullasari, Ajit S ; Shah, Sanjay ; Jain, Rajneesh ; Kumar, Premchand R ; Bahuleyan, C.G
Subjects: Aged ; Angioplasty ; Cardiovascular disease ; Care and treatment ; Clinical trials ; Complications and side effects ; Coronary Angiography ; Coronary artery ; Coronary Artery Disease - complications ; Coronary Artery Disease - mortality ; Coronary Artery Disease - therapy ; Coronary heart disease ; Coronary stenosis ; Diabetes ; Diabetes Complications - therapy ; Diabetes mellitus ; Dosage and administration ; Drug delivery ; Drug-Eluting Stents ; Everolimus ; Female ; Heart diseases ; Humans ; Implants ; Inhibitor drugs ; Intention to Treat Analysis ; Ischemia ; Logistic Models ; Male ; Middle Aged ; Myocardial infarction ; Paclitaxel ; Paclitaxel - administration & dosage ; Patients ; Percutaneous Coronary Intervention ; Rapamycin ; Retreatment - statistics & numerical data ; Sirolimus - administration & dosage ; Sirolimus - analogs & derivatives ; Stents ; Thrombosis ; Treatment Outcome
Is Part Of: The New England journal of medicine, 2015-10, Vol.373 (18), p.1709-1719
Description: In this trial, 1830 patients undergoing PCI were assigned to receive a paclitaxel-eluting or an everolimus-eluting stent. At 1 year, rates of target-vessel failure, MI, stent thrombosis, and target-lesion and target-vessel revascularization were higher with paclitaxel. Diabetes mellitus is a highly prevalent medical condition globally and is frequently associated with symptomatic coronary artery disease necessitating percutaneous coronary intervention (PCI). 1 There is, however, controversy regarding the choice of a drug-eluting stent in patients with diabetes. Fundamental to this debate is the finding that there is attenuation of the mammalian target of rapamycin (mTOR) signaling pathway in patients with type 2 diabetes, which suggests that stents eluting rapamycin (now called sirolimus) or its analogues (everolimus or zotarolimus) — often termed “limus-eluting” stents — could be less effective in this cohort, potentially making paclitaxel-eluting stents an attractive option. 2 It . . .
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1510188
PMID: 26466202
Source: ProQuest One Psychology
MEDLINE
Alma/SFX Local Collection
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1510188 ;PMID: 26466202

Searching Remote Databases, Please Wait